NGS molecular profiling with clinical-relevant turnaround times for precision oncology brings treatment decisions & personalized cancer treatment manufacturing within reach.
Genetic profiling using whole genome sequencing (WGS) or whole exome sequencing (WES) is combined with RNA-sequencing for clinical molecular profiling of a patients tumour. A turnaround time of ten days makes genetics and transcriptomics combination a valuable service for patient stratification within clinical trials, neoantigen prediction for manufacturing of personalized cancer vaccines or adoptive cell therapy, and for personalized treatment decisions.
Solutions that require only a minimal sample input and solutions for archival tissues allow you to profile all your precious samples. Differentiating between somatic and germline aberrations can be achieved by performing a WGS or WES on both tumour and normal samples while RNAseq confirms expression of the aberrations of interest.
“GenomeScan offers high quality services and is flexible where needed. myNEO specifically appreciates the open communication and pleasant working relation we have built up with the team.”